New hope for Tough-to-Treat blood cancer: testing a powerful drug duo

NCT ID NCT06660368

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 05, 2026 · Updated 22 times

Summary

This study is testing whether adding a drug called venetoclax to a standard chemotherapy combination (CLAG-M) works better for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The goal is to see if this new combination can more effectively clear remaining cancer cells and help patients live longer without their disease getting worse. About 52 participants will be randomly assigned to receive either the standard combination or the new combination.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Dana-Farber Cancer Institute
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

Contact

Contact

Contact

Contact

Contact

Contact

Contact

Contact

Contact

Conditions

Explore the condition pages connected to this study.

RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)